直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Even with Narrowing Claim Construction, PTAB Finds Dependent Claims Obvious on Remand

April 21, 2021

Authored and Edited by Yicong (Eve) Du; Brooke M Wilner; Amanda K. Murphy, Ph.D.

In Fitbit, Inc. v. Valencell, Inc., IPR2017-00319, Paper 73 (Apr. 5, 2021), on remand from the Federal Circuit, the Board determined the patentability of several previously omitted dependent claims and found them unpatentable as obvious.

Fitbit petitioned for Inter partes review of Valencell’s patent directed to a method of generating data output containing physiological and motion-related information, arguing that several of its claims were obvious.  In its original Final Written Decision, the Board found the patent’s sole independent claim to be obvious. But the Board refused to consider the obviousness argument of several dependent claims because, in the Board’s view, the obviousness challenge of these claims relied on improper claim construction and some of these claims also had dependency errors.

On appeal, the Federal Circuit vacated the Board’s decision and remanded for determination of patentability of these claims on the obviousness ground. The Court explained that the Board’s narrow construction may have no significance here and the dependency errors could be corrected through the parties’ agreement.  On remand, Fitbit again argued that the challenged dependent claims were unpatentable as obvious.

The key dispute was whether the asserted prior art references disclosed a key claim limitation present in the dependent claims: an “application-specific interface (API).”  In its original petition, the petitioner treated “application-specific interface (API)” as identical to “application programming interface.” In its original Final Written Decision, the Board found this construction to be overly broad. Instead, the Board construed “application-specific interface (API)” to mean “an interface which enables a particular application to utilize data obtained from hardware.”  Under this claim construction, an “application-specific interface (API)” is directed to a particular application, rather than broadly to different applications.  

On appeal, the Federal Circuit affirmed the Board’s construction, but noted that “the Board’s narrowing construction . . . may have no significance, where, as here, the claimed ‘application-specific interface’ performs the same function as an application programming interface, i.e., enabling a particular application to utilize data obtained from hardware.”

On remand, as in the original petition, Fitbit presented two independent obviousness grounds.  Valencell challenged each ground, arguing that because the application programming interfaces disclosed in the asserted references were generically applicable to different applications, they were not used with a particular application, as required by the claim under the Board’s construction.  Also, Valencell argued, even if the references’ interfaces could be used by a particular application, they were not directed to a particular application because they were designed to be interoperable—the opposite of application specific. 

In response, Fitbit argued that just because the interfaces could be used in different applications did not mean that they could not be applied to a “particular application.”  Rather, the interfaces could be used with a variety of particular applications, acting on information depending on the goal of the application.  By tailoring the interface to specific applications and devices, the references thus expressly taught interfaces directed to a particular application, regardless of whether those interfaces were also interoperable with other applications, Fitbit argued.

On the first ground, the Board agreed with Fitbit, ruling that the asserted references’ interfaces performed the same function as the recited “application-specific interface,” because not only were the interfaces used by a particular application, they could also be specifically tailored to each particular application.  Regarding the second ground, the Board found that Fitbit had not carried its burden to prove that the application programming interface disclosed in the references was specific enough to be an application-specific interface.  Having found that the challenged patent was obvious over the first ground, however, the Board found each of the challenged claims unpatentable as obvious.

Tags

Final Written Decision, United States Court of Appeals for the Federal Circuit (CAFC), Patent Trial and Appeal Board (PTAB), patentability, Obviousness (35 USC § 103)

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

Consumer Goods and Services

Consumer Products

Hospitality, Gaming, and Leisure

Sports, Fitness, and Outdoor Recreation

Related Offices

Atlanta, GA

Washington, DC

Contacts

Amanda K. Murphy, Ph.D.
Partner
London
+44 (0)20 7864 2814
Email

Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Articles

California Reaches Record $12.75 Million CCPA Settlement with General Motors Over Driver Data

June 4, 2026

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP